Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation

Gregory Yanik, Beth Hellerstedt, Joseph Custer, Raymond Hutchinson, Deborah Kwon, James L.M. Ferrara, Joseph Uberti, Kenneth R. Cooke

Research output: Contribution to journalArticle

Abstract

Acute pulmonary dysfunction remains a frequent and severe complication of hematopoietic stem cell transplantation (SCT). Almost half of the pulmonary insults that occur in this setting are noninfectious in origin and are referred to as idiopathic pneumonia syndrome (IPS). In this series of 3 patients, etanercept (Enbrel; Immunex, Seattle, WA), a soluble, dimeric tumor necrosis factor α-binding protein, was administered to 3 consecutive pediatric allogeneic BMT recipients with IPS. The administration of etanercept, in combination with standard immunosuppressive therapy, was well tolerated and associated with significant improvements in pulmonary dysfunction within the first week of theraphy. These data suggest that etanercept may represent a safe, non-cross-reactive, therapeutic option for patients with IPS and that clinical trials studying etanercept for this indication are warranted.

Original languageEnglish (US)
Pages (from-to)395-400
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume8
Issue number7
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Keywords

  • Allogeneic BMT
  • Pulmonary dysfunction
  • Tumor necrosis factor α (TNFα)

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation'. Together they form a unique fingerprint.

  • Cite this